Variability in Patients with Psoriasis: Insights into the Genotype–Phenotype Relationship  by Shelling, Michael L. & Kirsner, Robert S.
journal club
1784 Journal of Investigative Dermatology (2011), Volume 131 © 2011 The Society for Investigative Dermatology
For the article: http://dx.doi.org/10.1038/jid.2011.127
QUESTIONS
1. What roles do single-nucleotide polymorphisms, CCL4 and CCL4L, and CNV play in psoriasis?
2. How did the investigators perform their study, and what were the results?
3. What were the conclusions, and what are the clinical implications?
Patients with psoriasis often wonder why they have psoriasis and ask how the disease will 
affect them. Dermatologists can tell them that psoriasis is a chronic systemic inflammatory 
disorder resulting from a combination of predisposing genetic factors and environ mental 
triggers. Recent insights into the pathogenesis of psoriasis allow for more scientifically ori-
ented patients to appreciate the T helper type 17 pathway and the roles of IL-12, IL-22, and 
IL-23 (Nestle et al., 2009). Patients can take solace in the fact that there has been develop-
ment of highly effective therapeutic advances that target key components of this pathway. 
These promising therapies include antibodies to the p40 subunit of IL-12, blockade of 
IL-23 by ustekinumab (Leonardi et al., 2008) and briakinumab (Strober et al., 2011), newer 
molecules that target p38 MAPK (BMS-582949), and JAK/STAT (JAK3 antibody (CP-690,550)). 
New research utilizing genome-wide associations to search for relationships between 
genes for key chemokines, receptors, and other molecules is ongoing (Cargill et al., 2007). 
However, when patients ask what their future holds with respect to the course of this 
disease, dermatologists have less to say. New findings may help predict patients’ courses. Pedrosa et al. (this issue) recog-
nized the significance of an increase in C-C chemokine ligand 4 (CCL4) and CCL4-like (CCL4L) in patients with psoriasis 
and the potentially vital role these factors play in the recruitment of inflammatory cells. Thus, these researchers sought to 
evaluate the genetic polymorphisms of CCL4 in the susceptibility and/or modulation of the severity and course of psoria-
sis. Focusing on copy-number variation (CNV) and the rs4796195 single-nucleotide polymorphism that defines two allelic 
variants—the CCL4L1 original form (called L1) and the CCL4L2 minor allele—these researchers found that the distribution 
of these genetic variants, CNV, and protein levels were essentially equivalent in patients with psoriasis and in controls; 
however, in patients with psoriasis, CCL4L CNV and their respective protein levels were associated with greater risk of 
severe disease. Specifically, CCL4L1 allele frequency was higher in severe psoriasis, whereas CCL4L2 was more frequent 
in patients with milder disease.  
Although these results do not suggest a role for CCL4 and its variants in the genetic susceptibility for psoriasis, these 
host genetic factors may be important in the expression and clinical course for patients with psoriasis. Additionally, these 
results may lead to new approaches for therapeutic modulation. Through the following questions, we examine this paper 
in greater detail. For brief answers, please refer to the supplementary information online <http://www.nature.com/jid/
journal/v131/n9/suppinfo/jid2011229s1.html>.
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